PureTech's Components of Value
Learn more about our unique discovery process
Wholly Owned Pipeline
Cash at Puretech Parent Level
Founded Entities
1. Funding figure includes private equity financings, public offerings or grant awards. Funding figure excludes upfront payments and future milestone considerations received in conjunction with partnerships and collaborations such as those with Roche, Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly.
2. At the parent level, PureTech Health plc had cash and cash equivalents of $310.5 million at June 30, 2020, which does not reflect $101.6 million in proceeds received by PureTech in August 2020 from the sale of 1.3 million shares of Karuna common stock and excludes all other cash outflows from June 30, 2020, for total adjusted cash and cash equivalents of $412.1 million as of August 26, 2020.
3. PureTech Level Cash Reserves at June 30, 2020 represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $284.2 million and held at PureTech LYT Inc., our internal pipeline, of $26.3 million, all of which are wholly owned entities of PureTech, excluding cash balances and short-term investments of Controlled Founded Entities which are not wholly owned.
CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.
